Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.39 |
| ▸ | WNT1 | P04628 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | LIPC | P11150 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 3/20 | 0.32 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.31 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
| ▸ | GRK2 | P25098 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 1/20 | 0.31 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24617619 | 0.94 | ROCK2 (0.41) | ROCK2ROCK1WNT1GSK3BDYRK1A | |
| SCHEMBL30656404 | 0.87 | GRK2 (0.39) | ROCK2ROCK1WNT1GSK3BDYRK1A | |
| SCHEMBL24616909 | 0.86 | KCNH2 (0.38) | ROCK2ROCK1WNT1GSK3BDYRK1A | |
| SCHEMBL24617616 | 0.86 | MAPK1 (0.40) | ROCK2ROCK1WNT1GSK3BDYRK1A | |
| SCHEMBL29135975 | 0.84 | ROCK2 (0.49) | ROCK2ROCK1WNT1GSK3BDYRK1A | |
| SCHEMBL29778579 | 0.84 | ROCK2 (0.49) | ROCK2ROCK1WNT1GSK3BDYRK1A | |
| SCHEMBL24617035 | 0.83 | ROCK2 (0.42) | ROCK2ROCK1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL29778487 | 0.83 | ROCK2 (0.42) | ROCK2ROCK1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL24617338 | 0.83 | KDM4E (0.39) | ROCK2ROCK1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL29778373 | 0.82 | ROCK2 (0.41) | ROCK2ROCK1KDM4EHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240374582-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF | Genosco Inc. | 2024-11-14 | — | — | US | claimed |
| CN-117136186-A | Selective inhibitors of ROCK1 and ROCK2 protein kinases and uses thereof | 盖诺斯克公司 | 2023-11-28 | — | — | CN | claimed |
| EP-4274825-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF | Genosco Inc. (US) | 2023-11-15 | — | — | EP | claimed |
| WO-2022150381-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF | Genosco Inc. (US) | 2022-07-14 | — | — | WO | claimed |
| US-20240374582-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF | Genosco Inc. | 2024-11-14 | — | — | US | disclosed |
| CN-117136186-A | Selective inhibitors of ROCK1 and ROCK2 protein kinases and uses thereof | 盖诺斯克公司 | 2023-11-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374582-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND THEIR USES THEREOF | ROCK2, ROCK1, MYLK3 | ROCK2 1/4885ROCK1 2/4885WNT1 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.